Clinical trial · no report yet · Phase 2
NCT05630183
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
- NCT05630183 ↗
- Completed
- Agenus Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 3 | |
| Podcasts | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine With or Without Botensilimab (AGEN1181) in Patients With Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Botensilimab; Gemcitabine; Nab-paclitaxel
- Arms
- Part 1: Combination (Safety Lead-in Phase) · Experimental
- Part 2: Combination · Experimental
- Part 2: Standard of Care · Active comparator
- Enrollment
- 81
- Primary outcomes
- Progression-free Survival as Assessed by Investigator
- Sponsor
- Agenus Inc.
- Start
- Mar 27, 2023
- Primary completion
- Jan 5, 2026
- Results posted
- No
- Registry record
- NCT05630183 · updated Jun 11, 2026